Gilead Announces Lenacapavir Demonstrates Superior Efficacy Over Daily Oral Truvada in HIV Prevention for Women

Gelonghui June 20th | Gilead Sciences, Inc. stated that a late-stage study showed its injectable drug Lenacapavir demonstrated superior efficacy in preventing HIV infection in women compared to the company's existing daily pill, Truvada. The company noted that Lenacapavir was well-tolerated, with no significant or new safety issues arising during the study, and added that more detailed data would be released at future conferences. Lenacapavir, branded as Sunlenca, is administered twice a year and received U.S. approval in 2022 as a long-acting treatment option for HIV-infected individuals who have developed resistance to multiple drugs and undergone extensive prior treatment.